Comments

Tarsus Pharmaceuticals

TARSNASDAQ
PerksBuyCompare Brokers
PerksBuyCompare Brokers
$27.14
0.10.37%
At Close: -
$27.14
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Tarsus Pharmaceuticals (TARS) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$65.00
Lowest Price Target1
$30.00
Consensus Price Target1
$51.75

Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Click Here

Tarsus Pharmaceuticals (NASDAQ:TARS) Stock, Analyst Ratings, Price Targets, Forecasts

Tarsus Pharmaceuticals Inc has a consensus price target of $51.75 based on the ratings of 8 analysts. The high is $65 issued by Raymond James on October 8, 2021. The low is $30 issued by Goldman Sachs on February 29, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Barclays, and Oppenheimer on May 13, 2024, May 10, 2024, and May 9, 2024, respectively. With an average price target of $60.67 between HC Wainwright & Co., Barclays, and Oppenheimer, there's an implied 123.53% upside for Tarsus Pharmaceuticals Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
1
Feb
0
0
0
0
Mar
2
May
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.2
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Barclays
Oppenheimer
Jefferies
Goldman Sachs

1calculated from analyst ratings

Analyst Ratings for Tarsus Pharmaceuticals

Buy NowGet Alert
05/13/2024Buy Now124.76%HC Wainwright & Co.
Oren Livnat
$57 → $61MaintainsBuyGet Alert
05/10/2024Buy Now121.08%Barclays
Balaji Prasad
$50 → $60MaintainsOverweightGet Alert
05/09/2024Buy Now124.76%Oppenheimer
Francois Brisebois
$59 → $61MaintainsOutperformGet Alert
03/06/2024Buy Now62.12%Jefferies
Anthony Petrone
$30 → $44MaintainsBuyGet Alert
02/29/2024Buy Now10.54%Goldman Sachs
Andrea Tan
$19 → $30MaintainsNeutralGet Alert
02/28/2024Buy Now110.02%HC Wainwright & Co.
Oren Livnat
$50 → $57MaintainsBuyGet Alert
02/28/2024Buy Now84.23%Barclays
Balaji Prasad
$40 → $50MaintainsOverweightGet Alert
02/28/2024Buy Now117.39%Oppenheimer
Francois Brisebois
$55 → $59ReiteratesOutperform → OutperformGet Alert
11/20/2023Buy Now-29.99%Goldman Sachs
Andrea Tan
 → $19Initiates → NeutralGet Alert
11/10/2023Buy Now84.23%HC Wainwright & Co.
Oren Livnat
$42 → $50MaintainsBuyGet Alert
09/11/2023Buy Now80.55%Guggenheim
Eddie Hickman
$46 → $49MaintainsBuyGet Alert
08/14/2023Buy Now69.49%Guggenheim
Eddie Hickman
 → $46ReiteratesBuy → BuyGet Alert
08/11/2023Buy Now54.75%HC Wainwright & Co.
Oren Livnat
$50 → $42MaintainsBuyGet Alert
07/26/2023Buy Now84.23%HC Wainwright & Co.
Oren Livnat
$44 → $50MaintainsBuyGet Alert
07/18/2023Buy Now62.12%William Blair— → $44Initiates → OutperformGet Alert
06/26/2023Buy Now62.12%HC Wainwright & Co.
Oren Livnat
$40 → $44MaintainsBuyGet Alert
06/16/2023Buy Now54.75%Guggenheim
Eddie Hickman
$40 → $42MaintainsBuyGet Alert
05/18/2023Buy Now—Guggenheim
Eddie Hickman
—Initiates → BuyGet Alert
05/08/2023Buy Now58.44%Oppenheimer
Francois Brisebois
 → $43Reiterates → OutperformGet Alert
03/15/2023Buy Now47.38%HC Wainwright & Co.
Oren Livnat
 → $40Reiterates → BuyGet Alert
08/01/2022Buy Now47.38%Barclays
Balaji Prasad
 → $40Initiates → OverweightGet Alert
12/21/2021Buy Now47.38%HC Wainwright & Co.
Oren Livnat
 → $40Initiates → BuyGet Alert
11/23/2021Buy Now102.65%Oppenheimer
Francois Brisebois
—Initiates → OutperformGet Alert
10/08/2021Buy Now139.5%Raymond James
Dane Leone
—MaintainsStrong BuyGet Alert

FAQ

Q

What is the target price for Tarsus Pharmaceuticals (TARS) stock?

A

The latest price target for Tarsus Pharmaceuticals (NASDAQ:TARS) was reported by HC Wainwright & Co. on May 13, 2024. The analyst firm set a price target for $61.00 expecting TARS to rise to within 12 months (a possible 124.76% upside). 14 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Tarsus Pharmaceuticals (TARS)?

A

The latest analyst rating for Tarsus Pharmaceuticals (NASDAQ:TARS) was provided by HC Wainwright & Co., and Tarsus Pharmaceuticals maintained their buy rating.

Q

When was the last upgrade for Tarsus Pharmaceuticals (TARS)?

A

There is no last upgrade for Tarsus Pharmaceuticals

Q

When was the last downgrade for Tarsus Pharmaceuticals (TARS)?

A

There is no last downgrade for Tarsus Pharmaceuticals.

Q

When is the next analyst rating going to be posted or updated for Tarsus Pharmaceuticals (TARS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tarsus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tarsus Pharmaceuticals was filed on May 13, 2024 so you should expect the next rating to be made available sometime around May 13, 2025.

Q

Is the Analyst Rating Tarsus Pharmaceuticals (TARS) correct?

A

While ratings are subjective and will change, the latest Tarsus Pharmaceuticals (TARS) rating was a maintained with a price target of $57.00 to $61.00. The current price Tarsus Pharmaceuticals (TARS) is trading at is $27.14, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch